2,324 reports of this reaction
4.7% of all GALCANEZUMAB GNLM reports
#4 most reported adverse reaction
HEADACHE is the #4 most commonly reported adverse reaction for GALCANEZUMAB GNLM, manufactured by Eli Lilly and Company. There are 2,324 FDA adverse event reports linking GALCANEZUMAB GNLM to HEADACHE. This represents approximately 4.7% of all 49,086 adverse event reports for this drug.
Patients taking GALCANEZUMAB GNLM who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among GALCANEZUMAB GNLM users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for GALCANEZUMAB GNLM:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 2,324 FDA reports for GALCANEZUMAB GNLM. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 4.7% of all adverse event reports for GALCANEZUMAB GNLM, making it a notable side effect.
If you experience headache while taking GALCANEZUMAB GNLM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.